文献速递乳腺癌放疗

复发乳腺癌的保乳挽救手术联合术中电子线再照射:意大利放射治疗与临床肿瘤学协会(AIRO)多中心研究

Salvage Breast-Conserving Surgery and Reirradiation With Intraoperative Electrons for Recurrent Breast Cancer: A Multicentric Study on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
PubMed 文献 · Pract Radiat Oncol · 2024-07-18

该多中心研究纳入2002至2015年间8个意大利中心109例首次局部复发后接受重复象限切除联合术中电子线再照射的乳腺癌患者,中位随访11.7年,5年和10年第二局部复发累积发生率分别为12.2%和32.3%,第二局部复发显著降低乳腺癌特异性生存(HR 9.40,P<.001)。

要点

  • 109例保乳术后局部复发患者接受重复象限切除联合术中电子线再照射,中位随访11.7年。
  • 5年和10年第二局部复发累积发生率分别为12.2%和32.3%,约半数位于原复发部位。
  • 第二局部复发显著降低乳腺癌特异性生存(HR 9.40,P<.001)。

核心结论

  • 第二局部复发累积发生率在文献范围内但高于预期,对照射野范围和分割方案提出疑问。
  • 因第二局部复发使结局恶化,挽救方式必须仔细规划。

研究设计与样本

  • 2016至2018年建立收集8个意大利中心保乳术后术中电子线部分乳腺再照射数据的数据库。
  • 2002至2015年共109例患者接受保乳挽救再治疗。

主要发现

  • 首次局部复发中位大小0.9 cm(范围0.3-3.0),43.6%为luminal A型。
  • 术中电子线中位剂量18 Gy(范围12-21),中位限光筒直径4 cm(范围3-6)。
  • 第二局部复发5年累积发生率12.2%(95%CI 6.8%-19.2%),10年32.3%(95%CI 22.8%-42.2%),约半数与原复发同部位。
  • 5年和10年总生存率分别为95.2%和88.3%,乳腺癌特异性生存率分别为98%和94.5%。
  • 第二局部复发显著降低乳腺癌特异性生存(HR 9.40,P<.001)。

关键数值与推荐

  • 人表皮生长因子受体2状态和限光筒大小是独立局部复发预测因素。
  • ≥3级纤维化发生率为18.9%。
  • 患者报告的乳房外观良好/优秀比例为59.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intraoperative radiation therapy with electrons (IOERT) may represent a viable choice for partial breast reirradiation after repeat quadrantectomy for local recurrence (LR) for primary breast cancer (BC) in lieu of mastectomy. METHODS AND MATERIALS: A database collecting data on partial breast reirradiation with IOERT from 8 Italian centers was set up in 2016 to 2018, providing data on cumulative incidence (CumI) of second LR and survival with a long follow-up. RESULTS: From 2002 to 2015, 109 patients underwent the conservative retreatment. The median primary BC first LR interval was 11.1 years (range, 2.4-27.7). The median first LR size was 0.9 cm (range, 0.3-3.0), and 43.6% cases were luminal A. Median IOERT dose was 18 Gy (range, 12-21), and median collimator diameter was 4 cm (range, 3-6). Median follow-up duration was 11.7 years (IQR, 7.7-14.6). The second LR CumI was 12.2% (95% CI, 6.8%-19.2%) at 5 years and 32.3% at 10 years (95% CI, 22.8%-42.2%), occurring in the same site as the first LR in about half of the cases. Human epidermal growth factor receptor 2 status and collimator size were independent LR predictors. The 5- and 10-year overall survival rates were 95.2% and 88.3%, respectively, whereas 5- and 10-year BC-specific survival rates were 98% and 94.5%, respectively. The development of a second LR significantly reduced BC-specific survival (hazard ratio, 9.40; P < .001). Grade ≥3 fibrosis rate was 18.9%. Patient-reported cosmesis was good/excellent in 59.7% of the cases. CONCLUSIONS: Second LR CumI was within the range of the literature but higher than expected, opening questions on radiation field extension and fractionation schedule. Because a second LR worsened the outcome, salvage modality must be carefully planned.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Leonardi MC, Fodor AD, Frassoni S, et al. Salvage Breast-Conserving Surgery and Reirradiation With Intraoperative Electrons for Recurrent Breast Cancer: A Multicentric Study on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Pract Radiat Oncol. 2024. PMID: 39032597. doi:10.1016/j.prro.2024.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。